— 在此类疾病中,首个无进展生存期和总生存期均显示出显著获益的全球III期临床试验 —— SAFFRON III期研究的结果进一步巩固了泰瑞沙®作为EGFR突变肺癌基石疗法的地位 — 香港、上海和新泽西州弗洛勒姆公园2026年8月17日 /美通社/ -- 和黄医药(中国)有限公司(简称"和黄医药"或"HUTCHMED")(纳斯达克/伦敦证交所:HCM;香港交易所:13)今日宣布沃瑞沙®(...
Source Link— 在此类疾病中,首个无进展生存期和总生存期均显示出显著获益的全球III期临床试验 —— SAFFRON III期研究的结果进一步巩固了泰瑞沙®作为EGFR突变肺癌基石疗法的地位 — 香港、上海和新泽西州弗洛勒姆公园2026年8月17日 /美通社/ -- 和黄医药(中国)有限公司(简称"和黄医药"或"HUTCHMED")(纳斯达克/伦敦证交所:HCM;香港交易所:13)今日宣布沃瑞沙®(...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.